Cetrin, 10 mg 20 pcs.

Pharmacodynamics

Competitive histamine antagonist, hydroxyzine metabolite, blocks H1-histamine receptors. Prevents the development and facilitates the course of allergic reactions, has antipruritic and antiexudative effects. It affects the early stage of allergic reactions, limits the release of inflammatory mediators at the “late” stage of the allergic reaction, reduces the migration of eosinophils, neutrophils and basophils. It reduces capillary permeability, prevents the development of tissue edema, relieves smooth muscle spasm.

It eliminates the skin reaction to the introduction of histamine, specific allergens, as well as cooling (with cold urticaria). It reduces histamine-induced bronchoconstriction in mild bronchial asthma.
It has almost no anticholinergic and antiserotonin action.

In therapeutic doses the sedative effect is practically absent. The beginning of the effect after a single dose of 10 mg of cetirizine is 20 minutes and lasts for more than 24 hours. During the course of treatment tolerance to antihistamine action of cetirizine does not develop. After discontinuation of treatment the effect lasts up to 3 days.

Pharmacokinetics

Indications

Seasonal and year-round allergic rhinitis;
allergic conjunctivitis;
hay fever (hay fever);
urticaria, including chronic idiopathic urticaria;
itchy allergic dermatoses (atopic dermatitis, neurodermatitis);
angioedema (Quincke’s edema).

Pharmacological effect

Pharmacodynamics

A competitive histamine antagonist, a metabolite of hydroxyzine, blocks histamine H1 receptors. Prevents the development and facilitates the course of allergic reactions, has antipruritic and antiexudative effects. Affects the early stage of allergic reactions, limits the release of inflammatory mediators at the “late” stage of the allergic reaction, reduces the migration of eosinophils, neutrophils and basophils. Reduces capillary permeability, prevents the development of tissue edema, relieves spasm of smooth muscles.

Eliminates skin reactions to the introduction of histamine, specific allergens, as well as to cooling (with cold urticaria). Reduces histamine-induced bronchoconstriction in mild bronchial asthma.
It has practically no anticholinergic and antiserotonin effects.

In therapeutic doses it practically does not cause a sedative effect. The onset of the effect after a single dose of 10 mg of cetirizine is 20 minutes, lasts more than 24 hours. During the course of treatment, tolerance to the antihistamine effect of cetirizine does not develop. After stopping treatment, the effect lasts up to 3 days.

Pharmacokinetics

Special instructions

If the dose is exceeded 10 mg/day, the ability to react quickly may deteriorate.

In recommended doses, it does not enhance the effect of ethanol (at a concentration of no more than 0.8 g/l), however, it is recommended to refrain from using it during treatment.

For children (from 2 years old) Cetrin® is used in the form of syrup.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Cetirizine

Composition

Each film-coated tablet contains:

Active ingredient:

Cetirizine dihydrochloride 10 mg

Excipients:

Lactose

Corn starch

Povidone (K-30)

Magnesium stearate

Film casing:

Hypromellose

Macrogol 6000

Titanium dioxide

Talc

Sorbic acid

Polysorbate 80

Dimethicone

Pregnancy

Pregnancy

When analyzing prospective data on pregnancy outcomes, no cases of malformations, embryonic and neonatal toxicity with a clear cause-and-effect relationship were identified.

Animal studies have not revealed any direct or indirect adverse effects of cetirizine on the developing fetus (including in the postnatal period), pregnancy and childbirth.

There have been no controlled clinical studies on the safety of the drug during pregnancy, therefore cetirizine should not be used during pregnancy.

Breastfeeding

Cetirizine is excreted in breast milk in concentrations representing from 25% to 90% of the drug concentration in the blood plasma, depending on the time of administration. During breastfeeding, the drug is used after consultation with a doctor, if the expected benefit to the mother outweighs the potential risk to the child.

Fertility

Available data on the effects on human fertility are limited, but no adverse effects on fertility have been identified.

Contraindications

Hypersensitivity (including to hydroxyzine);
pregnancy, breastfeeding period;
children under 6 years of age (for this dosage form).
With caution:

Chronic renal failure (moderate and severe severity – correction of the dosage regimen is required), old age (possible decrease in glomerular filtration).

Side Effects

Cetrin® is usually well tolerated.

Interaction

No pharmacokinetic interactions were detected with pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, diazepam and glipizide.

Co-administration with theophylline (400 mg/day) leads to a decrease in the total clearance of cetirizine (theophylline kinetics does not change).

Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

Overdose

Symptoms (occur when taking a single dose of 50 mg) – dry mouth, drowsiness, urinary retention, constipation, anxiety, increased irritability.

Treatment: gastric lavage, prescription of symptomatic medications.

There is no specific antidote.

Hemodialysis is ineffective.

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

2 years.

Manufacturer

Dr. Reddy’s Laboratories Ltd, India